Evotec lowers 2026 financial outlook

Evotec SE, a drug discovery and development company, released preliminary, unaudited financial results for the second quarter and first half of 2026 on Tuesday, July 13, 2026. The company simultaneously significantly reduced its financial forecast for the full year 2026.

According to preliminary figures, Evotec expects Group revenues for the first half of 2026 to be approximately €300.1 million and adjusted Group EBITDA to be approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approximately €465.6 million.

Reflecting these figures, Evotec now anticipates full-year 2026 Group revenues in the range of €570 to €610 million, a decrease from the previously guided €700 to €780 million. The adjusted Group EBITDA is now projected to be between approximately -€70 and -€105 million, compared to the earlier forecast of €0 to €40 million.

The company's complete financial results for the second quarter and first half of 2026 are scheduled for publication on August 13, 2026.